ArticleACG case reports journal2026
Acute Severe Pancolitis After Initiation of a Calcitonin Gene-Related Peptide Receptor Antagonist: A Case Report.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcitonin gene-related peptide receptor antagonists (CGRP-RA) are increasingly prescribed for migraine prophylaxis. Gastrointestinal side effects have been described, but association with inflammatory bowel disease (IBD) is reported rarely. A 50-year-old woman with well-controlled ulcerative proctitis developed a severe flare shortly after commencing a CGRP-RA (atogepant). She presented with abdominal pain and diarrhea. Investigations showed elevated inflammatory markers, predominantly right sided colitis on computer tomography scan, as well as endoscopic and histological evidence of severe pancolitis. Treatment with intravenous steroids was ineffective, but she responded to infliximab and discontinuation of the CGRP antagonist. She was well at follow-up 3 months later. CGRP-RA may can be associated with IBD relapse or de novo disease. We present a case of acute flare with change in phenotype of disease. Clinicians should exercise caution when prescribing CGRP-RA in patients with known IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.